Single-dose rituximab as induction therapy in adult IgA vasculitis with rapidly progressive glomerulonephritis: a case report with peripheral blood CD19⁺ B-cell monitoring.

Naoko Kyoda, Rika Ago, Naoko Masuzawa, Masaki Yanamoto, Masaho Aizawa, Takao Masaki

Abstract readCase Reports

In one paragraph

Article in CEN case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Naoko KyodaDepartment of Nephrology, Miyoshi Central Hospital, Hiroshima, Japan.

Rika AgoDepartment of Nephrology, Miyoshi Central Hospital, Hiroshima, Japan. rikaago@gmail.com.ORCID 0000-0001-6427-6733

Naoko MasuzawaDepartment of Diagnostic Pathology, Otsu City Hospital, Shiga, Japan.

Masaki YanamotoDepartment of Nephrology, Miyoshi Central Hospital, Hiroshima, Japan.

Masaho AizawaDepartment of Nephrology, Miyoshi Central Hospital, Hiroshima, Japan.

Takao MasakiDepartment of Nephrology, Hiroshima University Hospital, Hiroshima, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Treatment for adult IgA vasculitis (IgAV), particularly severe cases, is not well established, although recent reports have suggested potential efficacy of rituximab (RTX). Here, we report a case highlighting the effectiveness of RTX based on pathophysiological and pathological considerations of IgAV, as well as a treatment protocol that has not been previously described. A 50-year-old man receiving glucocorticoids for cutaneous IgAV developed nephrotic syndrome and acute nephritic syndrome. Renal biopsy showed marked endocapillary and extracapillary proliferation with IgA deposition, consistent with severe IgAV nephritis. Despite glucocorticoid pulse therapy and intravenous cyclophosphamide, rapidly progressive glomerulonephritis ensued, prompting RTX initiation. With reference to peripheral blood CD19

Indexed as

B-LymphocytesGlomerulonephritisGlomerulonephritis, IGARituximabVasculitisAntigens, CD19BiopsyCyclophosphamideDisease ProgressionGlucocorticoidsHumansImmunoglobulin AImmunologic FactorsMaleMiddle AgedTreatment OutcomeAntigens, CD19CyclophosphamideGlucocorticoidsImmunoglobulin AImmunologic FactorsRituximabB-lymphocyte depletionHenoch–Schönlein purpuraIgA vasculitisRapidly progressive glomerulonephritisRituximab

Identifiers

PMID42050300

DOI10.1007/s13730-026-01118-1

PMCPMC13125695

What Socratic holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.